Skip to main content
. Author manuscript; available in PMC: 2011 Jul 12.
Published in final edited form as: Eur J Haematol. 2009 Jan;82(1):1–12. doi: 10.1111/j.1600-0609.2008.01171.x

Table 4.

Combination therapies in WM including nucleoside analogues with alkylating agents and rituximab

Study Regimen N Phase ORR %
Tam (96) Fludara/CTX 9 II 88
Tamburini (43) Fludara/CTX 49 II 78
Weber (32) Cladribine/CTX 37 II 84
Tam (44) Fludara/CTX/rituximab 5 II 80
Weber (32) Cladribine/CTX/rituximab 27 II 94
Hensel (97) Pentostatin/CTX/rituximab 17 II 90

Phase, phase of study; N, number of patients; ORR, overall response rate; CR, complete response; %, percentage.